Cargando…

Spotlight on New Antibiotics for the Treatment of Pneumonia

In the last years, the presence of multidrug-resistant (MDR) Gram-negative (like Klebsiella pneumoniae, Pseudomonas aeruginosa, Acinetobacter baumannii) and Gram-positive bacteria (mostly methicillin-resistant Staphylococcus aureus) was worldwide reported, limiting the options for an effective antib...

Descripción completa

Detalles Bibliográficos
Autor principal: Russo, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7755939/
https://www.ncbi.nlm.nih.gov/pubmed/33424231
http://dx.doi.org/10.1177/1179548420982786
_version_ 1783626438103007232
author Russo, Alessandro
author_facet Russo, Alessandro
author_sort Russo, Alessandro
collection PubMed
description In the last years, the presence of multidrug-resistant (MDR) Gram-negative (like Klebsiella pneumoniae, Pseudomonas aeruginosa, Acinetobacter baumannii) and Gram-positive bacteria (mostly methicillin-resistant Staphylococcus aureus) was worldwide reported, limiting the options for an effective antibiotic therapy. For these reasons, inappropriate antimicrobial therapy and delayed prescription can lead to an unfavorable outcome, especially in patients with pneumonia. New antibiotics approved belong to classes of antimicrobials, like beta-lactams with or without beta-lactamase inhibitors, aminoglycosides, oxazolidinones, quinolones, and tetracyclines, or based on new mechanisms of action. These new compounds show many advantages, including a broad spectrum of activity against MDR pathogens, good lung penetration, safety and tolerability, and finally the possibility of intravenous and/or oral formulations. However, the new antibiotics under development represent an important possible armamentarium against difficult-to-treat strains. The safety and clinical efficacy of these future drugs should be tested in clinical practice. In this review, there are reported characteristics of newly approved antibiotics that represent potential future options for the treatment of respiratory tract infections, including those caused by multidrug-resistant bacteria. Finally, the characteristics of the drugs under development are briefly reported.
format Online
Article
Text
id pubmed-7755939
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-77559392021-01-07 Spotlight on New Antibiotics for the Treatment of Pneumonia Russo, Alessandro Clin Med Insights Circ Respir Pulm Med Review In the last years, the presence of multidrug-resistant (MDR) Gram-negative (like Klebsiella pneumoniae, Pseudomonas aeruginosa, Acinetobacter baumannii) and Gram-positive bacteria (mostly methicillin-resistant Staphylococcus aureus) was worldwide reported, limiting the options for an effective antibiotic therapy. For these reasons, inappropriate antimicrobial therapy and delayed prescription can lead to an unfavorable outcome, especially in patients with pneumonia. New antibiotics approved belong to classes of antimicrobials, like beta-lactams with or without beta-lactamase inhibitors, aminoglycosides, oxazolidinones, quinolones, and tetracyclines, or based on new mechanisms of action. These new compounds show many advantages, including a broad spectrum of activity against MDR pathogens, good lung penetration, safety and tolerability, and finally the possibility of intravenous and/or oral formulations. However, the new antibiotics under development represent an important possible armamentarium against difficult-to-treat strains. The safety and clinical efficacy of these future drugs should be tested in clinical practice. In this review, there are reported characteristics of newly approved antibiotics that represent potential future options for the treatment of respiratory tract infections, including those caused by multidrug-resistant bacteria. Finally, the characteristics of the drugs under development are briefly reported. SAGE Publications 2020-12-20 /pmc/articles/PMC7755939/ /pubmed/33424231 http://dx.doi.org/10.1177/1179548420982786 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Review
Russo, Alessandro
Spotlight on New Antibiotics for the Treatment of Pneumonia
title Spotlight on New Antibiotics for the Treatment of Pneumonia
title_full Spotlight on New Antibiotics for the Treatment of Pneumonia
title_fullStr Spotlight on New Antibiotics for the Treatment of Pneumonia
title_full_unstemmed Spotlight on New Antibiotics for the Treatment of Pneumonia
title_short Spotlight on New Antibiotics for the Treatment of Pneumonia
title_sort spotlight on new antibiotics for the treatment of pneumonia
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7755939/
https://www.ncbi.nlm.nih.gov/pubmed/33424231
http://dx.doi.org/10.1177/1179548420982786
work_keys_str_mv AT russoalessandro spotlightonnewantibioticsforthetreatmentofpneumonia